Source-grounded facts extracted from AIM ImmunoTech Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
AIM ImmunoTech Inc. issued 306,494 shares of Common Stock of warrant to Ladenburg Thalmann & Co. Inc..
“The Company also agreed to issue to the Placement Agent warrants (the “Placement Agent Warrants”) to purchase 306,494 shares of Common Stock (the “Placement Agent Warrant Shares”)”
AIM ImmunoTech Inc. issued up to 10,216,476 shares of Common Stock of warrant to institutional investors.
“Class J warrants (the “Class J Warrants”) to purchase up to 10,216,476 shares of Common Stock (the “Class J Warrant Shares”), at an exercise price of $0.5189 per share”
AIM ImmunoTech Inc. issued up to 1,782,616 shares of Common Stock of warrant to institutional investors.
“pre-funded warrants (the “Pre-Funded Warrants”) to purchase up to an aggregate of 1,782,616 shares of Common Stock (the “Pre-Funded Warrant Shares”) at an exercise price of $0.001”
AIM ImmunoTech Inc. issued 771,503 shares of common stock to institutional investors for $0.5189 per share.
“the Company also agreed to issue and sell to such Investors, in a concurrent private placement, 771,503 shares of Common Stock at a per share price of $0.5189 (the “Unregistered Shares”)”
AIM ImmunoTech Inc. entered into Placement Agency Agreement with Ladenburg Thalmann & Co. Inc. valued at Cash fee equal to 8.0% and management fee equal to 0.75% of aggregate gross proceeds of Offerings, p (effective 2026-06-09).
“In connection with the Offerings, the Company also entered into a placement agency agreement, dated June 9, 2026 (the “Placement Agency Agreement”), with Ladenburg Thalmann & Co. Inc. (the “Placement Agent”), pursuant to which the Company agreed to pay the Placement Agent a cash fee equal to 8.0%, and a management fee equal to 0.75%, of the aggregate gross proceeds of the Offerings, and reimbursed the Placement Agent for certain expenses and legal fees.”
AIM ImmunoTech Inc. entered into Securities Purchase Agreement with institutional investors valued at Gross proceeds of approximately $1.3 million from Registered Offering, plus potential additional gro (effective 2026-06-09).
“On June 9, 2026, AIM ImmunoTech Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with institutional investors (the “Investors”), pursuant to which the Company agreed to issue and sell to such investors in a registered direct offering 2,554,119 shares (the “Shares”) of common stock, par value $0.001 per share (the “Common Stock”), of the Company, at an offering price of $0.5189 per share (such registered direct offering, the “Registered Offering”).”
AIM ImmunoTech Inc.: Changed voting standard for non-director proposals from majority of shares present to majority of votes cast on the proposal (effective 2026-06-09).
“effective as of June 9, 2026. The Amendment changed the voting standard for proposals other than the election of directors to provide that each other proposal submitted to a vote of stockholders shall, unless otherwise provided”
AIM ImmunoTech Inc. entered into Purchase Agreement with institutional investors valued at approximately $2.4 million (effective 2026-05-20).
“On May 20, 2026, AIM ImmunoTech Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with institutional investors (the “Investors”), pursuant to which the Company agreed to issue and sell to such investors in a registered direct offering 7,519,351 shares (the “Shares”) of common stock, par value $0.001 per share (the “Common Stock”), of the Company, at an offering price of $0.325 per share (such registered direct offering, the “Registered Offering”).”
AIM ImmunoTech Inc. amended Amendment #2 to Promissory Note with Streeterville Capital, LLC valued at extension fee in the amount of $10,000.00 (effective 2026-05-18).
“On May 18, 2026, the Company and the Lender entered into Amendment #2 to Promissory Note (the “Amendment”), which amended the Note and further extended the maturity date of the Note until June 30, 2027. Pursuant to the Amendment, the Company agreed to pay the Lender an extension fee in the amount of $10,000.00 (the “Extension Fee”), which Extension Fee was added to the outstanding balance of the Note.”
AIM ImmunoTech Inc. amended loan of $1,682,676.16 with Streeterville Capital, LLC maturing June 30, 2027.
“as a representation and warranty of the Company that, as of the date of the Amendment, the outstanding balance of the Note, following the application of the Extension Fee, was $1,682,676.16. The foregoing is only a summary of the material terms of the Amendment and does not purport to be a complete description of the rights and obligations of the parties thereunder.”
AIM ImmunoTech Inc. entered into Engagement Agreement with Ladenburg Thalmann & Co. Inc. (effective 2026-05-07).
“The Company entered into an engagement agreement (the “Engagement Agreement”) with Ladenburg Thalmann & Co. Inc. (the “Placement Agent”) to act as its placement agent in connection with the transactions summarized above.”
AIM ImmunoTech Inc. entered into Inducement Letter with holders of Existing May 2024 Warrants, Existing September 2024 Warrants, and Existing July 2025 Warrants valued at approximately $4.20 million (effective 2026-05-07).
“On May 7, 2026, AIM ImmunoTech Inc. (the “Company”) entered into a warrant exercise inducement offer letter agreement (the “Inducement Letter”) with holders (the “Holders”) of (i) Class A and Class B common stock purchase warrants issued on May 31, 2024”
AIM ImmunoTech Inc. amended Amendment No. 1 with Maxim Group LLC (effective 2026-04-10).
“On April 10, 2026, AIM ImmunoTech Inc. (the “Company”) entered into Amendment No. 1 (the “Amendment”) to that certain Equity Distribution Agreement dated April 1, 2025 (the “Sales Agreement”) with Maxim Group LLC (“Maxim”) to act as the Company’s exclusive sales agent with respect to the issuance and sale of up to $3,000,000 of the Company’s shares of common stock, par value $0.001 per share (the “Shares”), from time to time, in an at-the-market public offering (the “Offering”).”
AIM ImmunoTech Inc. incurred loan of $3,301,250 with Streeterville Capital, LLC at ten percent (10%) per annum compounded daily maturing 24 months from the date of its issuance.
“On November 18, 2025, AIM ImmunoTech Inc. (the “Company”, “we”, “us” or “our”) entered into a Note Purchase Agreement (the “ Note Purchase Agreement ”) with Streeterville Capital, LLC (the “ Investor ”) and consummated the sale to such Investor of an unsecured Promissory Note (the “ Note ”) with an original principal amount of $3,301,250 in a private placement (the “ Private Placement ”) that closed on November 18, 2025. The Note carries an original issuance discount of $781,250 and the Company agreed to pay $20,000 to the Investor to cover the Investor’s legal and administrative transaction costs, each of which were included in the original principal amount and deducted from the proceeds of the Note received by the Company which resulted in a purchase price received by the Company of $2,500,000. The Note bears interest at ten percent (10%) per annum compounded daily. The maturity date of the Note is 24 months from the date of its issuance (the “ Maturity Date ”).”
AIM ImmunoTech Inc. received a nyse_american noncompliance notice notice regarding stockholders equity (rules 1003(a)(ii), 1003(a)(iii)).
“June 17, 2025, AIM ImmunoTech Inc. (the “Company”) received a warning notification (the “Letter”) from the NYSE American LLC (the “NYSE American”) stating that the Company is not in compliance with the minimum stockholders’ equity requirements of Sections 1003(a)(ii) and 1003(a)(iii) of the NYSE American Company Guide (the “Company Guide”) requiring stockholders’ equity of $4.0 million or more if the Company has reported losses from continuing operations and/or net losses in three of the four most recent fiscal years and $6.0 million or more if the Company has reported losses from continuing o”
AIM ImmunoTech Inc.: Filed amendment to Articles of Incorporation effecting a 1-for-100 reverse stock split (effective 2025-06-10).
“On June 10, 2025, the Company filed an amendment to its Articles of Incorporation effecting a reverse split of its outstanding shares of Common Stock on a one for 100 basis”
AIM ImmunoTech Inc. received a nyse_american compliance regained notice regarding minimum bid price (rules 1003(f)(v)).
“June 11, 2025, AIM ImmunoTech Inc. (the “Company”) was notified by The NYSE American (the “Exchange”) that the Company has regained compliance with Section 1003(f)(v) of the NYSE American Company Guide (low selling price) and that trading in the Company’s Common Stock is expected to be reinstated on the Exchange on June 17, 2025 and the ticker symbol will be “AIM” upon reinstatement. The Company’s Common Stock currently trades on the OTC Pink under the symbol “AIMID”. The new CUSIP is 00901B303.”
AIM ImmunoTech Inc. received a nyse_american delisting notice notice regarding minimum bid price (rules 1003(f)(v)).
“April 4, 2025, AIM ImmunoTech Inc. (the “Company”) received notice from NYSE Regulation of the NYSE American LLC (“NYSE American”) that it had suspended trading of the Company’s common stock and determined to commence proceedings to delist the Company’s common stock from the NYSE American as a result of its determination that the Company is no longer suitable for listing pursuant to Section 1003(f)(v) of the NYSE American Company Guide due to the low selling price of the Company’s common stock. The Company has a right to a review of NYSE American’s determination to delist the Company’s common”
AIM ImmunoTech Inc.: Reduced quorum for stockholder meetings from 40% to 33 1/3% (effective 2025-02-24).
“On February 24, 2025, the Company adopted Restated and Amended Bylaws. The Restated and Amended Bylaws revise Section 1.6 Quorum, reducing the quorum for stockholder meetings from 40% to 33 and 1/3%.”
David I. Chemerow was appointed as Director at AIM ImmunoTech Inc..
“On February 26, 2025, AIM ImmunoTech Inc. (the "Company") issued a press release announcing the appointment of David I. Chemerow to its Board of Directors (the "Board"), effective February 24, 2025”
AIM ImmunoTech Inc. received a nyse_american deficiency notice notice regarding stockholders equity (rules 1003(a)(ii), 1003(a)(iii)).
“losses from continuing operations and/or net losses in its five most recent fiscal years, respectively. As of September 30, 2024, the Company had a stockholders’ deficit of $2.9 million and has had losses in the most recent five fiscal years ended December 31, 2023. The Company is now subject to the procedures and requirements of Section 1009 of the Company”
AIM ImmunoTech Inc. incurred loan of $3,301,250 with Streeterville Capital, LLC at ten percent (10%) per annum compounded daily maturing 24 months from the date of its issuance.
“On February 16, 2024, AIM ImmunoTech Inc. (the “Company”, “we”, “us” or “our”) entered into a Note Purchase Agreement (the “Note Purchase Agreement”) with Streeterville Capital, LLC (the “Investor”) and consummated the sale to such Investor of an unsecured Promissory Note (the “Note”) with an original principal amount of $3,301,250 in a private placement (the “Private Placement”) that closed on February 16, 2024. The Note carries an original issuance discount of $781,250 and the Company agreed to pay $20,000 to the Investor to cover the Investor’s legal and administrative transaction costs, each of which were included in the original principal amount and deducted from the proceeds of the Note received by the Company which resulted in a purchase price received by the Company of $2,500,000. The Note bears interest at ten percent (10%) per annum compounded daily. The maturity date of the Note is 24 months from the date of its issuance (the “Maturity Date”).”
AIM ImmunoTech Inc. entered into Note Purchase Agreement with Streeterville Capital, LLC valued at $3,301,250 original principal amount (effective 2024-02-16).
“On February 16, 2024, AIM ImmunoTech Inc. (the “Company”, “we”, “us” or “our”) entered into a Note Purchase Agreement (the “Note Purchase Agreement”) with Streeterville Capital, LLC (the “Investor”) and consummated the sale to such Investor of an unsecured Promissory Note (the “Note”) with an original principal amount of $3,301,250 in a private placement (the “Private Placement”) that closed on February 16, 2024.”
AIM ImmunoTech Inc. shareholders approved Approval, by non-binding advisory vote, of the frequency of executive compensation votes at the 2024-01-05 meeting.
“Proposal 4: Approval, by non-binding advisory vote, of the frequency of executive compensation votes : 1 Year: 10,460,322 2 Years: 137,119 3 Years: 1,176,713 Abstain: 664,828 Based on the results of the vote, and consistent with the Board’s recommendation, the Board has determined to hold a non-binding advisory vote regarding executive compensation every year until the next required non-binding advisory vote on the frequency of holding future votes regarding executive compensation.”
AIM ImmunoTech Inc. shareholders rejected Approval, by non-binding advisory vote, of the compensation of the Company’s named executive officers at the 2024-01-05 meeting.
“Proposal 3: Approval, by non-binding advisory vote, of the compensation of the Company’s named executive officers : For: 4,582,081 Against: 7,320,705 Abstain: 536,196”
AIM ImmunoTech Inc. shareholders approved Ratification of the selection of BDO USA, P.C. as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023 at the 2024-01-05 meeting.
“Proposal 2: Ratification of the selection of BDO USA, P.C. as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023 : For: 18,181,409 Against: 603,158 Abstain: 1,634,472”
AIM ImmunoTech Inc. shareholders approved Election of Directors at the 2024-01-05 meeting.
“Proposal 1: Election of Directors : The following four director nominees were each elected to serve a term ending at the Company’s Annual Meeting of Stockholders for 2024, or until their successors are duly elected and qualified: Nominees For Withheld Stewart L. Appelrouth 6,952,332 5,486,650 Nancy K. Bryan 10,522,260 1,916,722 Thomas K. Equels 10,294,728 2,144,254 William M. Mitchell 6,677,727 5,761,255”
AIM ImmunoTech Inc. entered into Amended and Restated Material Transfer and Research Agreement with Roswell Park Cancer Institute Corporation d/b/a Roswell Park Comprehensive Cancer Center (effective 2023-09-28).
“On September 28, 2023, AIM ImmunoTech Inc. (the “Company”) executed an Amended and Restated Material Transfer and Research Agreement (the “Agreement”) with Roswell Park Cancer Institute Corporation d/b/a Roswell Park Comprehensive Cancer Center (“Roswell”) that amends and restates the prior related agreements.”
AIM ImmunoTech Inc. entered into Material Transfer and Research Agreement with Japanese National Institute of Infectious Disease (effective 2023-05-22).
“On May 22, 2023, AIM ImmunoTech Inc. (the “Company”) and the Japanese National Institute of Infectious Disease (the “JNIID”) entered into a Material Transfer and Research Agreement (the “Agreement).”
AIM ImmunoTech Inc. entered into Unrestricted Grant Agreement with Erasmus University Medical Center (effective 2023-04-04).
“On April 4, 2023, AIM ImmunoTech Inc. (the “Company”) executed an Unrestricted Grant Agreement with Erasmus University Medical Center (“EUMC”) pursuant to which EUMC will use its best efforts to diligently carry out immune monitoring in pancreatic cancer patients.”
Nancy Bryan was appointed as Director at AIM ImmunoTech Inc..
“On March 30, 2023, AIM ImmunoTech Inc. (the “Company”) issued a press release announcing the appointment of Nancy Bryan to its Board of Directors (the “Board”), effective March 28, 2023”
AIM ImmunoTech Inc. entered into external sponsored collaborative clinical research agreement with Erasmus University Medical Center Rotterdam and AstraZeneca BV (effective 2023-01-13).
“On January 13, 2023, we entered into an external sponsored collaborative clinical research agreement with Erasmus University Medical Center Rotterdam and AstraZeneca BV, pursuant to which Erasmus is sponsoring and planning to perform an investigator-initiated clinical study, entitled Combining anti-PD-L1 immune checkpoint inhibitor durvalumab with TLR-3 agonist rintatolimod in patients with metastatic pancreatic ductal adenocarcinoma for therapy effect (the “Study”) in which it will use both study drugs provided by AstraZeneca and us.”
AIM ImmunoTech Inc. shareholders rejected Approval, by non-binding vote, of executive compensation at the 2022-11-03 meeting.
“Approval, by non-binding vote, of executive compensation : For: 2,036,994 Against: 10,213,253 Abstain: 108,287 Broker Non-Votes: 9,831,146”
AIM ImmunoTech Inc. shareholders approved Ratification of the selection of BDO USA, LLP as the Company's independent auditors for the fiscal year ending December 31, 2022 at the 2022-11-03 meeting.
“Ratification of the selection of BDO USA, LLP as the Company’s independent auditors for the fiscal year ending December 31, 2022 : For: 19,946,910 Against: 1,876,423 Abstain: 366,347”
AIM ImmunoTech Inc. shareholders approved Election of Directors at the 2022-11-03 meeting.
“Election of Directors : The following three director nominees were each elected to serve a term ending at the Company’s Annual Meeting of Stockholders for 2023, or until their successors are duly elected and qualified: Nominees For Withheld Broker Non-Votes Thomas K. Equels 7,652,988 4,705,546 9,831,146 William M. Mitchell 4,330,110 8,028,424 9,831,146 Stewart L. Appelrouth 4,319,085 8,039,449 9,831,146”
Ellen Lintal departed as Chief Financial Officer at AIM ImmunoTech Inc..
“On March 1, 2022, the Company entered into a consulting agreement with Ellen Lintal, who will step down as the Company’s Chief Financial Officer on April 4, 2022.”
Robert Dickey IV was appointed as Chief Financial Officer at AIM ImmunoTech Inc..
“On March 1, 2022, after review and approval by the Board of Directors, the Company entered into a consulting agreement with Foresite Advisors, LLC, a company wholly-owned by Robert Dickey IV, pursuant to which Mr. Dickey will serve as the Company’s new Chief Financial Officer effective April 4, 2022.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.